Elicio Therapeutics Inc. (NASDAQ: ELTX)
$5.2400
N/A ( +3.97% ) 11.4K
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.
Market Data
Open
$5.2400
Previous close
$5.2400
Volume
11.4K
Market cap
$56.55M
Day range
$5.0400 - $5.2550
52 week range
$2.9600 - $11.4500
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 67 | Mar 18, 2024 |
4 | Insider transactions | 1 | Feb 05, 2024 |
4 | Insider transactions | 1 | Feb 05, 2024 |
4 | Insider transactions | 1 | Feb 05, 2024 |
4 | Insider transactions | 1 | Feb 05, 2024 |
8-k | 8K-related | 29 | Feb 02, 2024 |
8-k | 8K-related | 18 | Jan 17, 2024 |
8-k | 8K-related | 12 | Jan 16, 2024 |
8-k | 8K-related | 38 | Jan 09, 2024 |
4 | Insider transactions | 1 | Dec 29, 2023 |